Many melanoma patients presented more advanced diseases during the COVID-19 pandemic, a study published in the Journal of the American Academy of Dermatology, revealed this on Tuesday.
Melanoma is a type of skin cancer that develops from the pigment-producing cells, known as melanocytes.
Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye (uveal melanoma).
According to dermatologists, other melanoma warning signs may include: –
“Pigmentation, redness or swelling that spreads outside the border of a spot to the surrounding skin, itching, tenderness or pain.
Changes in texture or scales, oozing or bleeding from an existing mole. Blurry vision or partial loss of sight or dark spots in the iris, a thin, annular structure in the eye, responsible for controlling the diameter and size of the pupil.
The researchers conducted a retrospective analysis on melanoma in 246 patients evaluated at one care center between the start of the COVID-19 pandemic on March 11, 2020, and January 12, 2021. These patients were compared with 246 patients evaluated between March 1, 2019, and March 10, 2020.
Many melanoma patients presented more advanced diseases during the COVID-19 pandemic. Of those in the pre-pandemic group 209 (85 per cent) presented with early-stage disease, while 37 (15 per cent) presented with metastatic disease. In the post-pandemic group, 200 (81.3 per cent) had the early-stage disease at presentation, while 46 (18.7 per cent) had metastatic disease.
Read Also: ‘Pfizer COVID-19 Pill Preventing Hospitalisations, Deaths’
A significant decrease in stage one disease presentation occurred during the post-pandemic group (28.5 per cent vs 40.7 per cent; P = .006), while a significant increase in stage III presentation occurred (30.5 per cent vs 21.1 per cent; P = .023).
Metastatic recurrence was also significantly increased in the post-pandemic group compared with the pre-pandemic group (7.7 per cent vs 3.3 per cent; P = .046), and the median time to recurrence was 60 months compared with 25.5 months.
Targeted therapy was more likely in patients in the post-COVID group, while immunotherapy was more likely in the pre-group.
Dr Saba Shaikh, Managing Director of the University of Pittsburgh Medical Center, Hillman Cancer Center, said that these findings suggest that patients had delays in coming for medical attention, likely resulting in more advanced diseases.
Shaikh said that these data underscored the importance of early detection and oncology referral for patients with melanoma, even during the pandemic.
Kindly like us on Facebook
